Potent and Selective Inhibitors of Human Reticulocyte 12/15-Lipoxygenase as Anti-Stroke Therapies

[Image: see text] A key challenge facing drug discovery today is variability of the drug target between species, such as with 12/15-lipoxygenase (12/15-LOX), which contributes to ischemic brain injury, but its human and rodent isozymes have different inhibitor specificities. In the current work, we...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Rai, Ganesha, Joshi, Netra, Jung, Joo Eun, Liu, Yu, Schultz, Lena, Yasgar, Adam, Perry, Steve, Diaz, Giovanni, Zhang, Qiangli, Kenyon, Victor, Jadhav, Ajit, Simeonov, Anton, Lo, Eng H., van Leyen, Klaus, Maloney, David J., Holman, Theodore R.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: American Chemical Society 2014
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4033661/
https://ncbi.nlm.nih.gov/pubmed/24684213
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/jm401915r
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg